. He can be reached at nsaraceno@mjhlifesciences.com.

Videos

In the final part of her Pharma Commerce video interview, Jen Butler, CCO at Pleio, emphasizes that as digital tools become central to patient support, there is value to balancing technology with empathy. 

Finding the Human Touch in a Wired World

In the third part of her Pharma Commerce video interview, Jen Butler, CCO at Pleio, argues that addressing patients’ emotional barriers is essential to maximizing ROI, improving adherence, and ensuring that existing support programs truly reach those who need them.

Emotional Support as Strategy

In the second part of her Pharma Commerce video interview, Jen Butler, CCO of Pleio, warns that without stronger education, communication, and pharmacist involvement, digital engagement risks becoming purely transactional.

Why DTC Drug Models Must Evolve From Access to True Patient Support

At LogiPharma USA, industry leaders from Tive, McKesson, and the broader healthcare logistics community discussed the sector’s transition from passive monitoring to real-time control, the growing influence of advanced therapies, and the importance of diversity and innovation in shaping the future of pharma supply chains.

LogiPharma USA 2025: Pharma Supply Chains Evolve Toward Real-Time Visibility and End-to-End Control

In the final part of her Pharma Commerce video interview, Megan Wetzel, VP, product, access & affordability at CoverMyMeds, shares how the right field reimbursement model structure ensures field teams have the insights and tools they need to overcome coverage barriers and accelerate patient access to therapy.

How Biopharma Companies Can Optimize Field Reimbursement Models

In the third part of her Pharma Commerce video interview, Megan Wetzel, VP, product, access & affordability at CoverMyMeds, explains that by educating provider offices on payer requirements, prior authorizations, and denial trends, field reimbursement managers help streamline complex reimbursement processes and reduce treatment delays.

The Unsung Allies Helping Patients Navigate Specialty Drug Access

In the second part of her Pharma Commerce video interview Megan Wetzel, VP, product, access & affordability at CoverMyMeds, describes how high development costs, personalized treatment models, and an aging population are intensifying the imbalance.

Why Rising Complexity and R&D Costs Are Fueling Specialty Drug Spending

Administrative hurdles and emotional isolation are driving therapy abandonment and worsening outcomes—Megan Wetzel of CoverMyMeds and Jen Butler of Pleio say the solution lies in combining streamlined access with stronger human connection.

The Hidden Costs of Prior Authorizations and Patient Loneliness

Kala Shankle, JD, HDA’s vice president of regulatory affairs, shares that as DSCSA traceability requirements take full effect, distributors and trading partners are preparing for long-term gains in supply chain security, recall efficiency, and counterfeit prevention.

HDA 2025 Traceability Seminar: DSCSA Compliance Ushers in a More Secure and Transparent Pharma Supply Chain

Kala Shankle, JD, HDA’s vice president of regulatory affairs, describes how FDA officials are signaling a balanced enforcement approach when it comes to DSCSA enforcement, expecting compliance efforts and documentation, but also recognizing that perfection will take time.